Kiniksa Pharmaceuticals (KNSA)
(Delayed Data from NSDQ)
$26.25 USD
+0.98 (3.88%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $26.26 +0.01 (0.04%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Kiniksa Pharmaceuticals, Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 270 | 220 | 39 | 0 | 0 |
Cost Of Goods | 33 | 23 | 9 | 0 | 0 |
Gross Profit | 237 | 197 | 29 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 262 | 188 | 186 | 157 | 170 |
Income After Depreciation & Amortization | -25 | 10 | -157 | -157 | -170 |
Non-Operating Income | 9 | 1 | 0 | 1 | 6 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -17 | 11 | -157 | -156 | -164 |
Income Taxes | -31 | -172 | 1 | 5 | -2 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 14 | 183 | -158 | -161 | -162 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 14 | 183 | -158 | -161 | -162 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -23 | 12 | -154 | -155 | -168 |
Depreciation & Amortization (Cash Flow) | 2 | 2 | 2 | 2 | 2 |
Income After Depreciation & Amortization | -25 | 10 | -157 | -157 | -170 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 71.92 | 70.42 | 68.58 | 61.84 | 54.05 |
Diluted EPS Before Non-Recurring Items | -0.34 | 2.60 | -2.30 | -2.61 | -2.99 |
Diluted Net EPS (GAAP) | 0.20 | 2.60 | -2.30 | -2.61 | -2.99 |
Fiscal Year end for Kiniksa Pharmaceuticals, Ltd falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 108.63 | 79.86 | 83.40 | 67.05 | 71.47 |
Cost Of Goods | 12.32 | 10.58 | 9.58 | 9.09 | 7.70 |
Gross Profit | 96.31 | 69.28 | 73.81 | 57.96 | 63.77 |
SG&A, R&D, and Dept/Amort Expenses | 96.43 | 85.81 | 73.73 | 68.89 | 66.93 |
Income After SG&A, R&D, and Dept/Amort Expenses | -0.12 | -16.53 | 0.08 | -10.93 | -3.16 |
Non-Operating Income | 2.42 | 2.27 | 2.37 | 2.43 | 1.92 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 2.30 | -14.28 | 2.45 | -8.50 | -1.24 |
Income Taxes | 6.21 | 3.43 | -22.79 | 5.36 | -16.21 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -3.91 | -17.70 | 25.24 | -13.86 | 14.97 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -3.91 | -17.70 | 25.24 | -13.86 | 14.97 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 71.01 | 70.63 | 72.66 | 70.19 | 71.64 |
Diluted EPS Before Non-Recurring Items | -0.06 | -0.25 | 0.04 | -0.20 | -0.02 |
Diluted Net EPS (GAAP) | -0.06 | -0.25 | 0.37 | -0.20 | 0.21 |